Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression

University of Leeds

Status

Completed

Conditions

Hypertension

Left Ventricular Hypertrophy

Treatments

Drug: Valsartan 160mg OD; Moxonidine 400mcg OD

Drug: Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD

Study type

Interventional

Funder types

Other

Identifiers

NCT00518479

PG/03/001

Details and patient eligibility

About

Uncontrolled high blood pressure can cause heart muscle 'thickening', and this increases the likelihood of complications and death. The high blood pressure explains some but not all of this increase in heart size. This study will investigate the other causes, and will measure the heart muscle 'thickness' very accurately using the latest and most accurate technique called cardiac magnetic resonance imaging (MRI). The best way to treat this heart thickening remains to be determined. We hope to be able to show that by specifically targeting the cause of heart muscle thickening we can reduce its occurrence more effectively than by other standard means of blood pressure treatment

Enrollment

42 patients

Sex

All

Ages

25 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Recently diagnosed essential hypertension (within 6 months).
Age 25 to 80 years; Weight < 100kg.
Sinus rhythm without significant ventricular or atrial ectopy.

Exclusion criteria

Current angiotensin II receptor antagonist or ACE Inhibitor treatment.
Contra-indication to any of the protocol anti-hypertensive agents.
Angina requiring treatment with a Beta blocker or calcium antagonist
Any disease affecting the autonomic nervous system e.g. congestive cardiac failure, diabetes, neurological disease, malignancy, pregnancy.
Contraindication to MRI (pacemaker, intra-orbital debris, intra-auricular implants, intra-cranial clips, history of claustrophobia, inability to lie supine for 15 minutes etc).